Who
Thomas Bures
Chief Accounting Officer
Company insider
Files Form 4 as: Chief Accounting Officer, Bruker; Chief Financial Officer, Palvella Therapeutics.
In numbers
- Trades disclosed
- 10
- Buys
- 1
- Sells
- 0
- Bought
- $24K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 27 Feb 2020
- Last trade
- 15 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Aug 2026filed 18 Aug 2026 | BRKR BrukerLife-science tools | SEC FORM 4 Code A | —4,035 at $0.00 | filing |
| 15 Aug 2026filed 18 Aug 2026 | BRKR BrukerLife-science tools | SEC FORM 4 Code A | —4,035 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | BRKR BrukerLife-science tools | SEC FORM 4 Code F | $10K274 at $36.51 | filing |
| 15 Feb 2026filed 18 Feb 2026 | BRKR BrukerLife-science tools | SEC FORM 4 Code F | $10K274 at $36.51 | filing |
| 10 Mar 2025filed 11 Mar 2025 | BRKR BrukerLife-science tools | SEC FORM 4 Bought | $24K500 at $47.40 | filing |
| 15 Feb 2025filed 19 Feb 2025 | BRKR BrukerLife-science tools | SEC FORM 4 Code A | —2,972 at $0.00 | filing |
| 24 Feb 2023filed 28 Feb 2023 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —249,080 at $0.00 | filing |
| 22 Feb 2022filed 24 Feb 2022 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —215,819 at $0.00 | filing |
| 4 Mar 2021filed 8 Mar 2021 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 27 Feb 2020filed 2 Mar 2020 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.